Comparison of incidence of common grades 3/4 nonhematologic toxicities according to number of delayed intensification phases
| . | Induction DI/DDI, % . | P . | Consolidation DI/DDI, % . | P . | IM-1 DI/DDI, % . | P . | DI-1 DI/DDI, % . | P . | IM-2 DI/DDI, % . | P . | DI-2 DDI, % . | P . | Maint DI/DDI, % . | P . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergic | 0/0.10 | .50 | 0/0 | — | 0.10/0.10 | 1.00 | 0.30/0.30 | 1.00 | 0/0 | — | 0.53 | — | 0/0 | — |
| Coagulation | 5.32/6.15 | .41 | 0.39/0.48 | .74 | 0.10/0.10 | .75 | 1.49/1.60 | .83 | 0/0 | — | 1.58 | — | 0.10/0 | .51 |
| Hepatic | 5.32/5.67 | .72 | 9.03/11.67 | .05 | 12.28/13.60 | .38 | 4.16/4.21 | .96 | 11.44/11.41 | .98 | 5.16 | — | 9.65/8.74 | .49 |
| Infections | 7.64/9.04 | .25 | 6.99/7.14 | .90 | 4.52/4.73 | .82 | 9.51/9.42 | .94 | 4.45/4.93 | .62 | 10.43 | — | 5.24/6.29 | .32 |
| Neurologic* | 3.87/3.94 | .93 | 3.30/3.66 | .65 | 1.96/3.45 | .04 | 1.09/2.81 | .005 | 0.81/1.95 | .03 | 2.00 | — | 0.82/0.85 | .94 |
| Seizures | 0.87/0.29 | .07 | 0.10/0.19 | .50 | 0.59/0.49 | .77 | 0.10/0.40 | .18 | 0.40/0.10 | .19 | 0.53 | — | 0/0 | — |
| Leuko† | 0/0 | — | 0/0 | — | 0/0 | — | 0/0.20 | .25 | 0/0 | — | 0 | — | 0.10/0 | .51 |
| Pancreatitis | 0.19/0.29 | .50 | 0.19/0.10 | .50 | 0/0.10 | .50 | 0.59/0.20 | .15 | 0.10/0 | .50 | 0 | — | 0.10/0 | .51 |
| Renal | 0.19/0.38 | .35 | 0.10/0 | .50 | 0/0 | — | 0.20/0 | .25 | 0/0 | — | 0 | — | 0/0 | — |
| . | Induction DI/DDI, % . | P . | Consolidation DI/DDI, % . | P . | IM-1 DI/DDI, % . | P . | DI-1 DI/DDI, % . | P . | IM-2 DI/DDI, % . | P . | DI-2 DDI, % . | P . | Maint DI/DDI, % . | P . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergic | 0/0.10 | .50 | 0/0 | — | 0.10/0.10 | 1.00 | 0.30/0.30 | 1.00 | 0/0 | — | 0.53 | — | 0/0 | — |
| Coagulation | 5.32/6.15 | .41 | 0.39/0.48 | .74 | 0.10/0.10 | .75 | 1.49/1.60 | .83 | 0/0 | — | 1.58 | — | 0.10/0 | .51 |
| Hepatic | 5.32/5.67 | .72 | 9.03/11.67 | .05 | 12.28/13.60 | .38 | 4.16/4.21 | .96 | 11.44/11.41 | .98 | 5.16 | — | 9.65/8.74 | .49 |
| Infections | 7.64/9.04 | .25 | 6.99/7.14 | .90 | 4.52/4.73 | .82 | 9.51/9.42 | .94 | 4.45/4.93 | .62 | 10.43 | — | 5.24/6.29 | .32 |
| Neurologic* | 3.87/3.94 | .93 | 3.30/3.66 | .65 | 1.96/3.45 | .04 | 1.09/2.81 | .005 | 0.81/1.95 | .03 | 2.00 | — | 0.82/0.85 | .94 |
| Seizures | 0.87/0.29 | .07 | 0.10/0.19 | .50 | 0.59/0.49 | .77 | 0.10/0.40 | .18 | 0.40/0.10 | .19 | 0.53 | — | 0/0 | — |
| Leuko† | 0/0 | — | 0/0 | — | 0/0 | — | 0/0.20 | .25 | 0/0 | — | 0 | — | 0.10/0 | .51 |
| Pancreatitis | 0.19/0.29 | .50 | 0.19/0.10 | .50 | 0/0.10 | .50 | 0.59/0.20 | .15 | 0.10/0 | .50 | 0 | — | 0.10/0 | .51 |
| Renal | 0.19/0.38 | .35 | 0.10/0 | .50 | 0/0 | — | 0.20/0 | .25 | 0/0 | — | 0 | — | 0/0 | — |
DI indicates single delayed intensification phase; DDI, double delayed intensification phase; IM, interim maintenance phase; and leuko, leukoencephalopathy.
Excluding seizures and leukoencephalopathy.